新型高选择性促甲状腺激素受体小分子拮抗剂S37a及其治疗格雷夫斯眼病的潜力
本研究针对格雷夫斯眼病缺乏靶向促甲状腺激素受体(TSHR)的病因治疗,通过高通量筛选和立体选择性合成获得分子S37,并分离出对映纯化合物S37a。S37a可在微摩尔水平抑制促甲状腺激素诱导的cAMP蓄积,且不影响密切相关的促卵泡激素和促黄体生成素受体,还能抑制人源单克隆促甲状腺激素刺激抗体M22、鼠源KSAb1及变构小分子激动剂C2对TSHR的激活。在表达TSHR的HEK 293细胞中,S37a可抑制格雷夫斯眼病患者血清中寡克隆促甲状腺激素刺激抗体引起的cAMP生成;小鼠体内初步药代动力学研究显示S37a无毒性,口服生物利用度达53%。
要点
- S37a是新型高选择性TSHR小分子拮抗剂,不作用于促卵泡激素和促黄体生成素受体。
- S37a可抑制促甲状腺激素、人源M22、鼠源KSAb1及小分子激动剂C2对TSHR的激活。
- S37a抑制格雷夫斯眼病患者血清中寡克隆促甲状腺激素刺激抗体诱导的cAMP生成。
核心结论
- S37a是一种新型高选择性TSHR抑制剂,具有进一步开发用于治疗格雷夫斯眼病的潜力。
研究设计与样本
- 通过在表达TSHR的中国仓鼠卵巢细胞中进行高通量筛选鉴定TSHR抑制剂。
- 对筛选命中物进行立体选择性合成获得含七个手性中心的分子S37,经对映体分离获得对映纯分子S37a。
- 在表达TSHR的HEK 293细胞中评估S37a对促甲状腺激素诱导的cAMP蓄积的拮抗作用。
- 在小鼠中进行初步体内药代动力学研究评估S37a的毒性和口服生物利用度。
主要发现
- S37a是微摩尔级拮抗剂,可抑制促甲状腺激素诱导的表达TSHR的HEK 293细胞中cAMP蓄积。
- S37a不影响密切相关的促卵泡激素受体和促黄体生成素受体。
- S37a可抑制人源单克隆促甲状腺激素刺激抗体M22、鼠源KSAb1及变构小分子激动剂C2对TSHR的激活。
- 在表达TSHR的HEK 293细胞中,S37a可抑制格雷夫斯眼病患者血清中高度富集的寡克隆促甲状腺激素刺激抗体引起的cAMP形成。
- 小鼠初步体内药代动力学研究显示S37a无毒性,口服生物利用度为53%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The thyrotropin receptor (TSHR) is the target for autoimmune thyroid stimulating antibodies (TSAb) triggering hyperthyroidism. Whereas elevated thyroid hormone synthesis by the thyroid in Graves' disease can be treated by antithyroid agents, for the pathogenic activation of TSHR in retro-orbital fibroblasts of the eye, leading to Graves' orbitopathy (GO), no causal TSHR directed therapy is available. METHODS: Due to the therapeutic gap for severe GO, TSHR inhibitors were identified by high-throughput screening in Chinese hamster ovary cells expressing the TSHR. Stereo-selective synthesis of the screening hits led to the molecule S37, which contains seven chiral centers. Enantiomeric separation of the molecule S37 resulted in the enantiopure molecule S37a-a micro-molar antagonist of thyrotropin-induced cyclic adenosine monophosphate accumulation in HEK 293 cells expressing the TSHR. RESULTS: The unique rigid bent shape of molecule S37a may mediate the observed high TSHR selectivity. Most importantly, the closely related follitropin and lutropin receptors were not affected by this compound. S37a not only inhibits the TSHR activation by thyrotropin itself but also activation by monoclonal TSAb M22 (human), KSAb1 (murine), and the allosteric small-molecule agonist C2. Disease-related ex vivo studies in HEK 293 cells expressing the TSHR showed that S37a also inhibits cyclic adenosine monophosphate formation by oligoclonal TSAb, which are highly enriched in GO patients' sera. Initial in vivo pharmacokinetic studies revealed no toxicity of S37a and a remarkable 53% oral bioavailability in mice. CONCLUSION: In summary, a novel highly selective inhibitor for the TSHR is presented, which has promising potential for further development for the treatment of GO.
引用
- Marcinkowski P, Hoyer I, Specker E, et al. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy. Thyroid. 2018. PMID: 30351237. doi:10.1089/thy.2018.0349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。